Pair Name	Honokiol, Cabozantinib
Disease Info	[ICD-11: 2C90.0]	Renal cell carcinoma		Investigative
Biological Phenomena	Induction-->Oxidative Stress
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	RUBCN	hsa9711
	Down-regulation	Expression	SQSTM1	hsa8878
	Down-regulation	Expression	NFE2L2	hsa4780
In Vitro Model	786-O	Renal cell carcinoma	Homo sapiens (Human)	CVCL_1051
	Caki-1	Clear cell renal cell carcinoma	Homo sapiens (Human)	CVCL_0234
	Caki-2	Papillary renal cell carcinoma	Homo sapiens (Human)	CVCL_0235
	ACHN	Papillary renal cell carcinoma	Homo sapiens (Human)	CVCL_1067
In Vivo Model	786-0 cells were subcutaneously injected into dorsal flank of 8-week-old male athymic nude mice and observed for the formation of tumors. The mice were then divided into four treatment groups (n = 5 mice per group): vehicle, XL-184, HNK, and XL-184 + HNK. Once the palpable tumor growth was observed, mice were treated with XL-184 (15 mg/kg), HNK (2 mg/kg) and XL-14 + HNK every alternate day for three weeks via intraperitoneal injection.
Result	Cabozantinib + Honokiol combination can significantly inhibit c-Met-induced and Nrf2-mediated anti-oxidant pathway in renal cancer cells to promote increased oxidative stress and tumor cell death.